Project Grant R01AI195944
- Federal Project Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $225,846 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 12, 2026, with completion targeted by May 31, 2028. The project advances antivirulence therapeutic strategies to combat antibiotic resistance by developing small-molecule inhibitors targeting Type IV Pili...
- Federal Project Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $422,355 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 23, 2025, with completion targeted for June 30, 2027. The grant funds mechanistic and structural studies examining the signaling histidine kinase GacS from Pseudomonas aeruginosa, a nosocomial...
- Federal Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $198,695 Project Grant award issued June 1, 2026, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The two-year research initiative, concluding May 31, 2028, focuses on discovery and development of novel antifungal therapeutics through repurposing neurokinin-1 (NK1) receptor antagonists. The...
- Federal Project Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $437,541 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate antisense therapeutic approaches for treating Clostridioides difficile infection (CDI). The award, effective February 2, 2026, through January 31, 2028, funds research focused on discovering...
- Federal Project Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $112,256 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 22, 2026, with completion targeted for March 31, 2027. The grant funds basic biomedical research investigating the epigenetic basis of monocyte exhaustion memory following sepsis, a condition...
- Federal Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $452,769 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 11, 2025, to conduct research on the impact of BDGR-49 treatment on Venezuelan Equine Encephalitis Virus (VEEV) induced neurological sequelae. The research addresses a critical public health gap by...
- Federal Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $414,482 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 24, 2025, with a completion date of June 30, 2027. The research focuses on developing an improved oncolytic virus therapeutic to treat glioblastoma, an aggressive brain cancer with poor prognosis. The project aims to...
- Federal Project Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $208,641 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 16, 2026, with completion targeted for June 30, 2028. The project, titled "The 'Hidden' Proteins in Aedes Aegypti," will systematically discover and characterize microproteins...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Virginia Polytechnic Institute & State University a $421,560 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct basic research on Brucella virulence mechanisms. The award, issued June 12, 2026, with completion targeted for May 31, 2028, supports research characterizing an alternative genetic pathway critical to Brucella pathogenesis,...
- Federal Project Grant Award Summary Virginia Polytechnic Institute & State University (Virginia Tech) received a $191,163 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 5, 2026 through January 31, 2028. The grant supports research on the transmission dynamics and pathogenesis of contemporary Mayaro virus (MAYV) strains, an emerging arbovirus endemic to...
Virginia Polytechnic Institute & State University (Virginia Tech) received an $808,607 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 9, 2026, with a completion date of June 30, 2031. The grant supports research to develop and optimize AI-designed antimicrobial peptides targeting ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), which represent a critical global health threat due to emerging antibiotic resistance to last-resort treatments. The project deliverables include: (1) optimization of peptide potency and safety through artificial intelligence-guided structure-based sequence screening to improve pharmacokinetics and minimize toxicity; (2) evaluation of in vivo efficacy of optimized peptides in systemic animal infection models, including septicemic peritonitis and vancomycin-resistant enterococci (VRE) rat endocarditis models; and (3) assessment of bactericidal efficacy and wound healing in a biofilm-infected diabetic pressure ulcer model. These research activities aim to advance novel antimicrobial peptide therapies as alternatives to conventional antibiotics, addressing a significant unmet medical need in treating multidrug-resistant bacterial infections.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $808.6k | 7/9/26 |